Status:
COMPLETED
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time th...
Eligibility Criteria
Inclusion
- Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
- Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.
- Patients may have to have tumor biopsy before and after treatment.
Exclusion
- Prior stem cell or bone marrow transplant
- Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse
- Active or unstable cardiac disease or history of heart attack within 6 months
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00141297
Start Date
September 1 2004
End Date
December 1 2014
Last Update
January 5 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
3
Abramson Cancer Center Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
4
Pharmacy/PCAM/West Pavillion
Philadelphia, Pennsylvania, United States, 19104